| SC 13D/A | 2020-09-08 | BAY CITY CAPITAL LLC | MADRIGAL PHARMACEUTICALS, INC. | 2,864,074 | 18.6% | EDGAR |
| SC 13D/A | 2020-06-01 | BAY CITY CAPITAL LLC | MADRIGAL PHARMACEUTICALS, INC. | 4,305,079 | 27.9% | EDGAR |
| SC 13G/A | 2020-02-14 | HealthCor Management, L.P. | MADRIGAL PHARMACEUTICALS, INC. | 1,088,310 | 7.1% | EDGAR |
| SC 13G/A | 2020-02-14 | Capital Research Global Investors | MADRIGAL PHARMACEUTICALS, INC. | 1,697,119 | 10.9% | EDGAR |
| SC 13G | 2020-02-11 | VANGUARD GROUP INC | MADRIGAL PHARMACEUTICALS, INC. | 785,441 | 5.1% | EDGAR |
| SC 13G | 2020-01-28 | WELLINGTON MANAGEMENT GROUP LLP | MADRIGAL PHARMACEUTICALS, INC. | 957,146 | 6.2% | EDGAR |
| SC 13D/A | 2019-12-13 | BAY CITY CAPITAL LLC | MADRIGAL PHARMACEUTICALS, INC. | 4,177,854 | 27.1% | EDGAR |
| SC 13D/A | 2019-10-17 | BAY CITY CAPITAL LLC | MADRIGAL PHARMACEUTICALS, INC. | 5,377,854 | 34.8% | EDGAR |
| SC 13D/A | 2019-10-17 | FRIEDMAN PAUL A | MADRIGAL PHARMACEUTICALS, INC. | 1,166,595 | 7.4% | EDGAR |
| SC 13D/A | 2019-10-17 | Taub Rebecca | MADRIGAL PHARMACEUTICALS, INC. | 1,276,282 | 8.2% | EDGAR |
| SC 13G/A | 2019-02-14 | Capital Research Global Investors | MADRIGAL PHARMACEUTICALS, INC. | 1,664,452 | 10.8% | EDGAR |
| SC 13G/A | 2019-02-13 | FMR LLC | MADRIGAL PHARMACEUTICALS, INC. | 34,241 | 0.2% | EDGAR |
| SC 13G | 2019-02-13 | BAKER BROS. ADVISORS LP | MADRIGAL PHARMACEUTICALS, INC. | 1,169,278 | 7.6% | EDGAR |
| SC 13G | 2019-02-07 | HealthCor Management, L.P. | MADRIGAL PHARMACEUTICALS, INC. | 800,000 | 5.2% | EDGAR |
| SC 13G | 2018-08-10 | Capital Research Global Investors | MADRIGAL PHARMACEUTICALS, INC. | 1,664,452 | 10.8% | EDGAR |
| SC 13G | 2018-02-13 | FMR LLC | MADRIGAL PHARMACEUTICALS, INC. | 717,125 | 5.0% | EDGAR |
| SC 13D/A | 2016-08-01 | CAXTON CORP | SYNTA PHARMACEUTICALS CORP | 318,068 | 2.8% | EDGAR |
| SC 13D/A | 2016-07-26 | CAXTON CORP | SYNTA PHARMACEUTICALS CORP | 344,509 | 3.0% | EDGAR |
| SC 13D | 2016-04-28 | Madrigal Pharmaceuticals, Inc. | SYNTA PHARMACEUTICALS CORP | 31,553,861 | 21.0% | EDGAR |
| SC 13D/A | 2016-04-15 | CAXTON CORP | SYNTA PHARMACEUTICALS CORP | 12,057,869 | 8.7% | EDGAR |